OrbiMed’s Prelude Therapeutics PRLD Stock Holding History

OrbiMed’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.3M	Hold	10,909,256	–	–	0.74%	40
2025 Q4	$31.6M	Hold	10,909,256	–	–	0.65%	46
2025 Q3	$15.7M	Hold	10,909,256	–	–	0.37%	61
2025 Q2	$8.83M	Hold	10,909,256	–	–	0.22%	63
2025 Q1	$8.38M	Hold	10,909,256	–	–	0.2%	67
2024 Q4	$13.9M	Hold	10,909,256	–	–	0.29%	63
2024 Q3	$22.6M	Hold	10,909,256	–	–	0.41%	62
2024 Q2	$41.6M	Hold	10,909,256	–	–	0.82%	38
2024 Q1	$51.7M	Hold	10,909,256	–	–	0.95%	37
2023 Q4	$46.6M	Hold	10,909,256	–	–	0.93%	40
2023 Q3	$33.7M	Hold	10,909,256	–	–	0.72%	52
2023 Q2	$49.1M	Buy	10,909,256 +869,565	+9%	+$5.2M	0.89%	41
2023 Q1	$57.2M	Hold	10,039,691	–	–	1.12%	28
2022 Q4	$60.6M	Hold	10,039,691	–	–	1.16%	31
2022 Q3	$66.4K	Hold	10,039,691	–	–	1.23%	27
2022 Q2	$52.4K	Hold	10,039,691	–	–	0.95%	35
2022 Q1	$69.3M	Hold	10,039,691	–	–	1.12%	32
2021 Q4	$125M	Hold	10,039,691	–	–	1.61%	21
2021 Q3	$314M	Hold	10,039,691	–	–	3.45%	2
2021 Q2	$287M	Hold	10,039,691	–	–	2.91%	6
2021 Q1	$435M	Sell	10,039,691 -5,555,186	-36%	-$369M	4.07%	3
2020 Q4	$1.12B	Hold	15,594,877	–	–	9.76%	1
2020 Q3	$470M	Buy	+15,594,877	New	+$440M	5.91%	1

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed's PRLD Position: Q1 2026 in Review

OrbiMed held its Prelude Therapeutics (PRLD) position steady in Q1 2026 at 10,909,256 shares worth $37.3M. The position accounts for 0.74% of the portfolio, ranked #40.

OrbiMed first reported a position in PRLD in Q3 2020 and has held it in 23 quarters since. The position peaked at $1.12B in Q4 2020. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

OrbiMed held 10,909,256 shares of Prelude Therapeutics worth $37.3M as of Q1 2026.
OrbiMed left its Prelude Therapeutics share count unchanged in Q1 2026.
Prelude Therapeutics made up 0.74% of OrbiMed's portfolio in Q1 2026, its #40 holding.
OrbiMed first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 23 quarters since.
OrbiMed's Prelude Therapeutics position peaked at $1.12B in Q4 2020.
55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.